866-997-4948(US-Canada Toll Free)

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 71 Pages

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2016, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline landscape.

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. Treatment includes NSAIDs, acetaminophen, blood transfusion and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 4, 1, 1 and 1 respectively.Vaso-Occlusive Crisis Associated With Sickle Cell Disease.

Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Overview 7
Therapeutics Development 8
Pipeline Products for Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Overview 8
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics under Development by Companies 9
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Products under Development by Companies 13
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Companies Involved in Therapeutics Development 14
AstraZeneca Plc 14
Bristol-Myers Squibb Company 15
Complexa Inc 16
Dilaforette AB 17
Gilead Sciences Inc 18
Novartis AG 19
NuvOx Pharma LLC 20
Pfizer Inc 21
Seattle Genetics Inc 22
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
apixaban - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
CXA-10 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
NVX-508 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
regadenoson - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
rivipansel sodium - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
SelG-1 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
sevuparin sodium - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
SGD-2083 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ticagrelor - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects 61
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products 62
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Product Development Milestones 63
Featured News & Press Releases 63
Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel 63
Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology 63
Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel 64
Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015 65
Nov 06, 2014: GlycoMimetics Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting 65
Sep 26, 2014: GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel 65
Jul 01, 2014: GlycoMimetics Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Rivipansel (GMI-1070) 66
May 21, 2014: GlycoMimetics Receives $15 Million Payment from Pfizer in Connection with Planned Initiation of Phase 3 Trial 66
Sep 13, 2013: GlycoMimetics Announces EMAs Granting of Orphan Drug Status in European Union for GMI-1070 in Sickle Cell Disease 67
Aug 19, 2013: Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises 67
Jan 17, 2013: GlycoMimetics Completes Enrollment In Phase II Sickle Cell Disease Study With Lead Drug Candidate GMI-1070 68
Dec 11, 2012: Glycomimetics Presents Data From Pilot Study Of GMI-1070 At ASH Annual Meeting 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables
Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by AstraZeneca Plc, H2 2016 14
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Company, H2 2016 15
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Complexa Inc, H2 2016 16
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Dilaforette AB, H2 2016 17
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Gilead Sciences Inc, H2 2016 18
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Novartis AG, H2 2016 19
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by NuvOx Pharma LLC, H2 2016 20
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Pfizer Inc, H2 2016 21
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Seattle Genetics Inc, H2 2016 22
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Stage and Target, H2 2016 25
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects, H2 2016 61
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products, H2 2016 62

List of Figures
Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Targets, H2 2016 24
Number of Products by Stage and Targets, H2 2016 24
Number of Products by Mechanism of Actions, H2 2016 26
Number of Products by Stage and Mechanism of Actions, H2 2016 26
Number of Products by Routes of Administration, H2 2016 28
Number of Products by Stage and Routes of Administration, H2 2016 28
Number of Products by Molecule Types, H2 2016 30
Number of Products by Stage and Molecule Types, H2 2016 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *